Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

pro BTD for B OM is that cisplat for head and neck CA, q 3 weekly Is considered better.

This helps IPIX given their data set showing p<0.05 benefit in that very subgroup

The numbers are small, and that is a problem, but results are suggestive of a real benefit.

Spoke to sister who is a Rad Onc and she says preferred q 3 week for patients able to tolerate it- more aggressive, higher dosing, better outcomes.

That is good for us as shareholders

What is bad is that no news yet and no deal
yes- I just bought more shares

I hope and pray they can get a deal done

B OM and B UP are potential game changers, not to mention the rest of the brilacidin franchise
So sad to see where things stand now-that is to say, on the brink of failure